Biosimilars and the Problem with PBMs: Interview with Juliana M. Reed, Executive Director of the Biosimilars Forum

Xtalks Life Science Podcast

English - July 19, 2023 09:00 - 35 minutes - 24.5 MB
Life Sciences Science pharma pharmaceuticals biotech biotechnology medical device life science drug safety clinical research clinical trials drug development Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Opioid Use Disorder and Brixadi Approval: Interview with Dr. Joshua Cohen, Chief Medical Officer at Braeburn

Next Episode: Point-of-Care Testing for Infectious Diseases: Senzo CEO Jeremy Stackawitz Speaks About Company’s New Lateral Flow Technology

Uptake of biosimilars is lagging in the US, but why? In this episode, Sarah interviews Juliana M. Reed, Executive Director of the Biosimilars Forum, to find out the real barriers to widespread access to biosimilars, and how these problems could be addressed.

Julie discusses the role of pharmacy benefit managers (PBMs) and the incentives that keep them from listing most biosimilars on their formularies. She applauds the recent launch of multiple new biosimilars for the blockbuster biologic Humira and explains why this moment is pivotal for the biosimilars industry and the US healthcare system as a whole.

Mentioned during this episode:

Interview with Dr. Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung Bioepis – Xtalks Life Science Podcast Ep. 110

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Twitter Mentions

@xtalks